CFDE Data Portal | Search PTPN12

	Label	Description
	PTPN12 Gene (Entity type)	ENSG00000127947 - protein tyrosine phosphatase non-receptor type 12
	DFFA Gene (Entity type)	ENSG00000160049 - DNA fragmentation factor subunit alpha
	HCK Gene (Entity type)	ENSG00000101336 - HCK proto-oncogene, Src family tyrosine kinase
	HINT1 Gene (Entity type)	ENSG00000169567 - histidine triad nucleotide binding protein 1
	GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE242555 1 V 0 NICOTINAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 10 V 5 CISPLATIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE147662 3 V 1 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE248769 1 V 0 SORAFENIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE169356 ivermectin prostate gland 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

PTPN12

ENSG00000127947 - protein tyrosine phosphatase non-receptor type 12

DFFA

ENSG00000160049 - DNA fragmentation factor subunit alpha

HCK

ENSG00000101336 - HCK proto-oncogene, Src family tyrosine kinase

HINT1

ENSG00000169567 - histidine triad nucleotide binding protein 1

GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN

A Gene Set from LINCS

GSE242555 1 V 0 NICOTINAMIDE HUMAN DN

A Gene Set from LINCS

GSE216043 10 V 5 CISPLATIN HUMAN UP

A Gene Set from LINCS

GSE147662 3 V 1 NICOTINAMIDE MOUSE UP

A Gene Set from LINCS

GSE248769 1 V 0 SORAFENIB HUMAN UP

A Gene Set from LINCS

GSE169356 ivermectin prostate gland 0 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.